Immutep (ASX:IMM) has unveiled a pair of significant clinical developments that underscore its ambition to reshape cancer treatment, announcing positive results in both soft tissue sarcoma and first-line non-small cell lung cancer at the 2025 European Society for Medical Oncology Congress in Berlin. …
Immutep unveils dual breakthroughs at ESMO 2025, strengthening case for Efti across multiple tumour types
October 20, 2025 Australian Biotech
Latest Video
New Stories
-
Cartherics and Catalent deepen partnership to accelerate next generation cell therapies
April 10, 2026 - - Australian Biotech -
Lower official co-payment but patients paying for more unsubsidised medicines
April 10, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 10 April
April 10, 2026 - - Podcast -
Is there any example of another review or inquiry taking this long?
April 10, 2026 - - Latest News -
Rewriting the rules of PBS negotiations to deliver a patient-first reset
April 10, 2026 - - Latest News -
A decade of readiness as AVITA medical expands burn response capability
April 9, 2026 - - Australian Biotech -
Moderna names Carolyn Tucek-Szabo to lead Australia and New Zealand operations
April 9, 2026 - - Latest News